- Home
- NTRB vs IKNA Comparison
NTRB vs IKNA Comparison
Compare NTRB & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- IKNA
- Stock Information
- Founded
- NTRB 2016
- IKNA 2016
- Country
- NTRB United States
- IKNA United States
- Employees
- NTRB N/A
- IKNA N/A
- Industry
- NTRB Industrial Specialties
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- NTRB Health Care
- IKNA Health Care
- Exchange
- NTRB Nasdaq
- IKNA Nasdaq
- Market Cap
- NTRB 59.1M
- IKNA 63.7M
- IPO Year
- NTRB N/A
- IKNA 2021
- Fundamental
- Price
- NTRB $8.00
- IKNA $1.36
- Analyst Decision
- NTRB Buy
- IKNA Strong Buy
- Analyst Count
- NTRB 1
- IKNA 1
- Target Price
- NTRB $13.00
- IKNA $4.00
- AVG Volume (30 Days)
- NTRB 133.7K
- IKNA 60.0K
- Earning Date
- NTRB 09-02-2025
- IKNA 08-07-2025
- Dividend Yield
- NTRB N/A
- IKNA N/A
- EPS Growth
- NTRB N/A
- IKNA N/A
- EPS
- NTRB N/A
- IKNA N/A
- Revenue
- NTRB $2,398,437.00
- IKNA N/A
- Revenue This Year
- NTRB $560.75
- IKNA N/A
- Revenue Next Year
- NTRB $588.39
- IKNA N/A
- P/E Ratio
- NTRB N/A
- IKNA N/A
- Revenue Growth
- NTRB 18.92
- IKNA N/A
- 52 Week Low
- NTRB $3.72
- IKNA $0.97
- 52 Week High
- NTRB $11.78
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- NTRB 51.71
- IKNA 53.81
- Support Level
- NTRB $7.93
- IKNA $1.31
- Resistance Level
- NTRB $11.68
- IKNA $1.42
- Average True Range (ATR)
- NTRB 0.69
- IKNA 0.05
- MACD
- NTRB -0.07
- IKNA -0.00
- Stochastic Oscillator
- NTRB 20.96
- IKNA 45.45
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.